Jul. 20 at 11:30 AM
$PMN with the Platform 💊 of PMN310 for Alzheimer Disease ProMIS is also targeting:
5. Frontotemporal Dementia (FTD) Pharmaceutical sales 2026: approx. USD 120 to 250 million (market for specific, targeted drugs). Leading companies (market leaders): There is no disease-modifying therapy specifically approved for FTD; the market is served entirely through off-label use. Revenues are distributed among major generics manufacturers (such as Teva,
$VTRS , or
$SDZXF ) for the use of selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics to manage behavioral symptoms. Promising pipeline candidate:
$ALEC (in collaboration with
$GLAXO.NSE ) is developing latazanemab (AL001)—this represents the future growth potential for the FTD niche market.
